Takeda's ORZEYFUL (oveporexton) approved by FDA for narcolepsy type 1
- FDA approved Takeda’s ORZEYFUL (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for treatment of narcolepsy type 1 in adults.
- Narcolepsy type 1 affects an estimated 120,000 people in the U.S.
- DEA will determine controlled-substance scheduling within 90 days; product to be dispensed via specialty pharmacy after scheduling.
- Pooled Phase 3 safety data: insomnia in 60% (2 mg BID) and 55% (1 mg BID) vs 1% placebo; urinary frequency in 58% and 53% vs 5% placebo; CPK >5x ULN in 11% of treated patients vs 5% placebo.
Regulatory decision
The U.S. Food and Drug Administration approved ORZEYFUL (oveporexton), an oral OX2R agonist from Takeda, for the treatment of narcolepsy type 1 in adults. It is described as the first approved orexin therapy in the U.S. and the only medicine indicated to address the underlying orexin deficiency driving NT1 rather than only individual symptoms.
Clinical evidence
The approval is based on a global Phase 3 program including FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002). Trials showed statistically significant improvements across the full range of NT1 symptoms, including excessive daytime sleepiness, cataplexy and health-related quality of life, with oveporexton generally well tolerated in the studied populations.
Safety and prescribing notes
Common adverse reactions include insomnia, urinary frequency/urgency and salivary hypersecretion. Pooled Phase 3 rates included insomnia in 60% (2 mg BID) and 55% (1 mg BID) versus 1% with placebo, and urinary frequency in 58% and 53% versus 5% placebo. Asymptomatic creatine phosphokinase elevations >5×ULN occurred in 11% of treated patients versus 5% placebo; two cases led to discontinuation. ORZEYFUL is contraindicated with strong CYP3A inhibitors and should be avoided in severe hepatic impairment (Child‑Pugh C) and in patients on dialysis (eGFR <15 mL/min).
Availability and commercial notes
The Drug Enforcement Administration will assign a controlled-substance schedule within an expected 90 days; following scheduling, ORZEYFUL will be distributed via specialty pharmacy. Takeda does not expect the approval to materially affect its consolidated financial forecast for the fiscal year ending March 31, 2027.
Source: Takeda
